Trial Number

080-20

Age range

18 years and older

Gender

Male or Female

Enrolling Patients

Yes

Early embolectomy therapy of pulmonary embolism can potentially reduce the risks of serious adverse events such as cardiopulmonary deterioration and death. Traditional anticoagulation therapy does not dissolve clots (only prevents them from getting bigger) and can take months for complete resolution. There is a lack of effective and safe catheter therapies that can remove a large amount of clot. The CAPERE® Embolectomy System is designed to safely and effectively remove large clot burden without the use of thrombolytics or aspiration, thus fulfilling the need for a rapid and safe treatment modality for acute pulmonary embolism. While other currently available devices require longer ICU stays and multiple treatment sessions, the CAPERE® Embolectomy System is designed to achieve clot retrieval with one (1) treatment session. The CAPERE® Embolectomy System is being studied to evaluate the clinical safety and efficacy under an Investigational Device Exemption (IDE).

Principal Investigator

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.

Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.